{"organizations": ["Dawson James Small Cap Growth Conference"], "uuid": "099beff84721511e8533bf87adc0f13608130cb4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-biology-technology", "section_title": "Latest Biology Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/biology-technology-1/TapImmune-to-Present-at-Dawson-James-Small-Cap-Growth-Conference-in-Florida-on-October-15--2015-34325-1/", "country": "US", "title": "TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015", "spam_score": 0.0, "site_type": "news", "published": "2015-10-13T16:57:00.000+03:00", "replies_count": 0, "uuid": "099beff84721511e8533bf87adc0f13608130cb4"}, "author": "", "url": "http://www.bio-medicine.org/biology-technology-1/TapImmune-to-Present-at-Dawson-James-Small-Cap-Growth-Conference-in-Florida-on-October-15--2015-34325-1/", "ord_in_thread": 0, "title": "TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015", "locations": ["Florida"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Date:10/13/2015 \nJACKSONVILLE, Florida , October 13, 2015 /PRNewswire/ -- \nTapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured presenting company at the Dawson James Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on October 15, 2015. \nAt 9.30 am in Preserve Ballroom C, Board member and Strategic Advisor, Dr. John N. Bonfiglio , will present an overall update and review of TapImmune's currently planned Phase 2 clinical development programs in breast and ovarian cancer. For the live webcast please register at http://www.wsw.com/webcast/dawson/tpiv/. \nTapImmune CEO Glynn Wilson commented, \"Having recently completed significant clinical and corporate advancements, we look forward to presenting investors with our upcoming pipeline of Phase 2 studies and associated milestones that we believe will be important catalysts for our company's growth.\" \nThe full day conference will include two track presentations from over 30 companies in healthcare/technology and consumer sectors including an uplist \"Boot Camp\". The conference is attended by Dawson James' institutional, family office and high net worth clients. Dawson James Securities is a full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors. \nAbout TapImmune Inc. \nTapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details. \nForward-Looking Statement Disclaimer \nThis release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are \"forward-looking statements\". Forward-looking statements are by their nature subject to risks, uncertainties and other \nfactors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements. \nContacts: TapImmune Inc., Glynn Wilson , Ph.D. Chairman & CEO, +1-866-359-754 '/>\"/>", "external_links": [], "published": "2015-10-13T16:57:00.000+03:00", "crawled": "2015-10-14T16:19:53.471+03:00", "highlightTitle": ""}